Literature DB >> 32107559

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.

Lukas Ronner1, Nikolai Podoltsev2, Jason Gotlib3, Mark L Heaney4, Andrew T Kuykendall5, Casey O'Connell6, Jamile Shammo7, Angela G Fleischman8, Robyn M Scherber9, Ruben Mesa9, Abdulraheem Yacoub10, Cecelia Perkins3, Shelby Meckstroth11, Lindsey Behlman2, Matthew Chiaramonte4, Mahta Salehi6, Kimia Ziadkhanpour1, Hellen Nguyen8, Olivia Siwoski10, Annie Kwok Hung9, Michelle Janania Martinez9, Jenny Nguyen8, Sagar Patel6, Revathi Kollipara7, Ami Dave7, Megan Randall7, Michael Grant7, Mitchell Harrison7, Paola Fernandez Soto7, Douglas Tremblay12, Ronald Hoffman12, Erin Moshier13, John Mascarenhas12.   

Abstract

There are unresolved questions regarding the association between persistent leukocytosis and risk of thrombosis and disease evolution in polycythemia vera (PV), as much of the published literature on the topic does not appropriately use repeated-measures data or time-dependent modeling to answer these questions. To address this knowledge gap, we analyzed a retrospective database of 520 PV patients seen at 10 academic institutions across the United States. Taking hematologic laboratory data at ∼3-month intervals (or as available) for all patients for duration of follow-up, we used group-based trajectory modeling to identify latent clusters of patients who follow distinct trajectories with regard to their leukocyte, hematocrit, and platelet counts over time. We then tested the association between trajectory membership and hazard of 2 major outcomes: thrombosis and disease evolution to myelofibrosis, myelodysplastic syndrome, or acute myeloid leukemia. Controlling for relevant covariates, we found that persistently elevated leukocyte trajectories were not associated with the hazard of a thrombotic event (P = .4163), but were significantly associated with increased hazard of disease evolution in an ascending stepwise manner (overall P = .0002). In addition, we found that neither hematocrit nor platelet count was significantly associated with the hazard of thrombosis or disease evolution.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 32107559      PMCID: PMC7205813          DOI: 10.1182/blood.2019003347

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

Review 1.  Polycythemia vera: myths, mechanisms, and management.

Authors:  Jerry L Spivak
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

Review 2.  Inflammation, atherosclerosis, and coronary artery disease.

Authors:  Göran K Hansson
Journal:  N Engl J Med       Date:  2005-04-21       Impact factor: 91.245

3.  Group-based trajectory modeling in clinical research.

Authors:  Daniel S Nagin; Candice L Odgers
Journal:  Annu Rev Clin Psychol       Date:  2010       Impact factor: 18.561

4.  Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.

Authors:  Alessandra Carobbio; Alberto Ferrari; Arianna Masciulli; Arianna Ghirardi; Giovanni Barosi; Tiziano Barbui
Journal:  Blood Adv       Date:  2019-06-11

5.  Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance.

Authors:  Daniela Barraco; Sonia Cerquozzi; Curtis A Hanson; Rhett P Ketterling; Animesh D Pardanani; Naseema Gangat; Ayalew Tefferi
Journal:  Br J Haematol       Date:  2017-06-09       Impact factor: 6.998

6.  Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project.

Authors:  Giovanni Barosi; Ruben Mesa; Guido Finazzi; Claire Harrison; Jean-Jacques Kiladjian; Eva Lengfelder; Mary F McMullin; Francesco Passamonti; Alessandro M Vannucchi; Carlos Besses; Heinz Gisslinger; Jan Samuelsson; Srdan Verstovsek; Ronald Hoffman; Animesh Pardanani; Francisco Cervantes; Ayalew Tefferi; Tiziano Barbui
Journal:  Blood       Date:  2013-04-16       Impact factor: 22.113

7.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

8.  Cardiovascular events and intensity of treatment in polycythemia vera.

Authors:  Roberto Marchioli; Guido Finazzi; Giorgina Specchia; Rossella Cacciola; Riccardo Cavazzina; Daniela Cilloni; Valerio De Stefano; Elena Elli; Alessandra Iurlo; Roberto Latagliata; Francesca Lunghi; Monia Lunghi; Rosa Maria Marfisi; Pellegrino Musto; Arianna Masciulli; Caterina Musolino; Nicola Cascavilla; Giovanni Quarta; Maria Luigia Randi; Davide Rapezzi; Marco Ruggeri; Elisa Rumi; Anna Rita Scortechini; Simone Santini; Marco Scarano; Sergio Siragusa; Antonio Spadea; Alessia Tieghi; Emanuele Angelucci; Giuseppe Visani; Alessandro Maria Vannucchi; Tiziano Barbui
Journal:  N Engl J Med       Date:  2012-12-08       Impact factor: 91.245

Review 9.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

Review 10.  Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.

Authors:  S Cerquozzi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-11-13       Impact factor: 11.037

View more
  14 in total

Review 1.  Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era.

Authors:  Jan Philipp Bewersdorf; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2020-11-01       Impact factor: 2.929

2.  JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.

Authors:  Zuzanna Kanduła; Michał Janowski; Barbara Więckowska; Edyta Paczkowska; Krzysztof Lewandowski
Journal:  J Cancer Res Clin Oncol       Date:  2022-10-15       Impact factor: 4.322

Review 3.  Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia.

Authors:  Ivan Krecak; Marko Lucijanic; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2022-08-06       Impact factor: 4.213

4.  European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera.

Authors:  Douglas Tremblay; Andrew Srisuwananukorn; Lukas Ronner; Nikolai Podoltsev; Jason Gotlib; Mark L Heaney; Andrew Kuykendall; Casey L O'Connell; Jamile M Shammo; Angela Fleischman; Ruben Mesa; Abdulraheem Yacoub; Ronald Hoffman; Erin Moshier; Nicole Zubizarreta; John Mascarenhas
Journal:  Hemasphere       Date:  2022-05-11

Review 5.  Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.

Authors:  Alison R Moliterno; Yelena Z Ginzburg; Ronald Hoffman
Journal:  Blood       Date:  2021-03-04       Impact factor: 22.113

Review 6.  Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms.

Authors:  Francisca Ferrer-Marín; Ernesto José Cuenca-Zamora; Pedro Jesús Guijarro-Carrillo; Raúl Teruel-Montoya
Journal:  Int J Mol Sci       Date:  2021-01-24       Impact factor: 5.923

Review 7.  Polycythemia vera: historical oversights, diagnostic details, and therapeutic views.

Authors:  Ayalew Tefferi; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Leukemia       Date:  2021-09-03       Impact factor: 11.528

8.  The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.

Authors:  John Mascarenhas; Francesco Passamonti; Kate Burbury; Tarec Christoffer El-Galaly; Aaron Gerds; Vikas Gupta; Brian Higgins; Kathrin Wonde; Candice Jamois; Bruno Kovic; Ling-Yuh Huw; Sudhakar Katakam; Margherita Maffioli; Ruben Mesa; Jeanne Palmer; Marta Bellini; David M Ross; Alessandro M Vannucchi; Abdulraheem Yacoub
Journal:  Blood Adv       Date:  2022-02-22

9.  Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis.

Authors:  Jan Philipp Bewersdorf; Smith Giri; Rong Wang; Nikolai Podoltsev; Robert T Williams; Martin S Tallman; Raajit K Rampal; Amer M Zeidan; Maximilian Stahl
Journal:  Leukemia       Date:  2020-09-01       Impact factor: 11.528

Review 10.  The possible role of mutated endothelial cells in myeloproliferative neoplasms.

Authors:  Mirko Farina; Domenico Russo; Ronald Hoffman
Journal:  Haematologica       Date:  2021-11-01       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.